The American Academy of Pain Management
The American Academy of Pain Management is an inclusive, interdisciplinary, and integrative organization serving clinicians who treat people with pain through education, setting standards of care, and advocacy.
The American Academy of Pain Management News and Research is made possible, in part, by educational grants from the following sponsers:
Product News and Clinical Trial Results
Zogenix And Astellas announce data published showing the benefits of SUMAVEL(TM) DosePro(TM) needle-free delivery system
October 23, 2009 Source: Zogenix, Inc
Zogenix, Inc. and Astellas Pharma US, Inc. announced that positive results from two clinical studies of new SUMAVEL DosePro (sumatriptan injection) needle-free delivery system will be published in the November 2009 issue of Headache. The first study showed a rate of absorption of subcutaneous sumatriptan that has been previously shown to correlate with rapid and complete relief of migraine symptoms. The second showed that an overwhelming majority of patients successfully used the new needle-free system during a migraine attack on their first attempt.
[Story]
Zolmitriptan nasal spray effective as acute treatment for cluster headache
October 21, 2009 Source: Headache
Pain from cluster headaches is substantially relieved within half an hour after dosing with 5 to 10 mg of zolmitriptan nasal spray, according to an individual subject meta-analysis of two randomized, crossover trials. The 10-mg dose was significantly more effective than the lower dose and both doses were significantly more effective than placebo.
[Story]
Forest Laboratories and Cypress Bioscience announce study shows patients treated with Savella experience improvements in pain and physical function
October 20, 2009 Source: Savella
According to results from a large-scale, Phase III clinical trial, Savella® (milnacipran HCI) 100 mg/day (50 mg twice daily) demonstrated statistically significant and clinically meaningful concurrent improvements in pain, patient global assessment, and physical function. Savella is a selective serotonin and norepinephrine dual reuptake inhibitor that was approved by the U.S. Food and Drug Administration earlier this year for the management of fibromyalgia.
[Story]
Combo pill an option for diabetes-related nerve pain
October 20, 2009 Source: Reuters Health o
According to a new study, a single pill containing the pain relievers tramadol and acetaminophen (TA) is as effective as the drug gabapentin for treating diabetes-related nerve pain. Thus, the current findings support TA as a suitable alternative to gabapentin as a first-line therapy for painful diabetic neuropathy.
[Story]
Pacira's Phase III study of EXPAREL(TM) meets primary pain relief endpoint
October 20, 2009 Source: Pacira Pharmaceuticals, Inc
Pacira Pharmaceuticals, Inc. announced today that its Phase III study of its new analgesic EXPAREL(TM) in patients undergoing a bunionectomy procedure met its primary endpoint. The study showed a statistically significant reduction in area under the curve analysis of the NRS scores in the subjects receiving EXPAREL(TM) compared to placebo over the first 24 hours following surgery. The difference continued to be statistically significant through 36 hours.
[Story]
King pain drug videos misleading
October 20, 2009 Source: Reuters
Two video news releases for King Pharmaceuticals' pain drug Embeda left out a warning about the risk of a fatal overdose, U.S. regulators said in a letter released on Tuesday. King agreed, during a conference call in August, to comply with an FDA request to stop using the materials.
[Story]
Purdue Pharma L.P. receives 2009 NCPA Corporate Recognition Award
October 19, 2009 Source: Purdue Pharma L.P.
Purdue Pharma L.P. was honored on Monday with the 2009 NCPA Corporate Recognition Award at the National Community Pharmacists Association's 111th Annual Convention and Trade Exposition held October 17-21 in New Orleans, LA. The annual award, sponsored by the NCPA Foundation, recognizes companies for their support of independent community pharmacies.
[Story]
BioElectronics to announce results of acetaminophen comparison study
November 11, 2009 Source: BioElectronics Corporation
BioElectronics Corp. recently released results of a study compares the effects of ActiPatch® Therapy to acetaminophen in the form of Extra Strength Tylenol® for the treatment of Delayed Onset Muscle Soreness (DOMS). The results for the pilot section of this study were highly significant with the ActiPatch group scoring its average level of muscle soreness and discomfort at much lower levels compared to either the control group or the acetaminophen treatment group.
[Story]
Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting
November 11, 2009 Source: Osteotech, Inc
Osteotech, Inc. today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. MagniFuse is a patented, next-generation technology platform that supports a family of high-performance, procedure-specific products that provide for simplified, precision grafting when injury or disease creates a need for bone fusion or new bone growth.
[Story]